{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:28:39Z","timestamp":1786994919014,"version":"build-2736575974"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["F31DA043921"],"award-info":[{"award-number":["F31DA043921"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01DA037287"],"award-info":[{"award-number":["R01DA037287"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01DA024022"],"award-info":[{"award-number":["R01DA024022"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse (NIDA) Intramural Research Programs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.neuropharm.2019.01.020","type":"journal-article","created":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T01:27:53Z","timestamp":1547774873000},"page":"200-209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats"],"prefix":"10.1016","volume":"150","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7862-1913","authenticated-orcid":false,"given":"Kathryn L.","family":"Schwienteck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaycee E.","family":"Faunce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenner C.","family":"Rice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Obeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce E.","family":"Blough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis W.","family":"Grim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Stevens","family":"Negus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4949-5246","authenticated-orcid":false,"given":"Matthew L.","family":"Banks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2019.01.020_bib1","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S0022-3565(25)23036-1","article-title":"Assessment of relative intrinsic activity of mu-opioid analgesics in vivo by using beta-funaltrexamine","volume":"255","author":"Adams","year":"1990","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2019.01.020_bib2","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0022-3565(24)29358-7","article-title":"Stimulation of guanosine-5\u2032-o-(3-[35S]thio)triphosphate binding in digitonin-permeabilized C6 rat glioma cells: evidence for an organized association of \u03bc-opioid receptors and G protein","volume":"298","author":"Alt","year":"2001","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2019.01.020_bib3","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1177\/0269881116689257","article-title":"Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents","volume":"31","author":"Altarifi","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.01.020_bib4","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1124\/jpet.110.169276","article-title":"Antinociceptive interactions between mu-opioid receptor agonists and the serotonin uptake inhibitor clomipramine in rhesus monkeys: role of mu agonist efficacy","volume":"335","author":"Banks","year":"2010","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2019.01.020_bib5","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1124\/pr.115.011163","article-title":"Sex differences in animal models: focus on addiction","volume":"68","author":"Becker","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2019.01.020_bib6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s002130000567","article-title":"Agonist efficacy, drug dependence, and medications development: preclinical evaluation of opioid, dopaminergic, and GABAA-ergic ligands","volume":"153","author":"Bergman","year":"2000","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.01.020_bib7","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF00421388","article-title":"Theoretical and methodological considerations on drug discrimination learning","volume":"46","author":"Colpaert","year":"1976","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.neuropharm.2019.01.020_bib8","doi-asserted-by":"crossref","first-page":"S153","DOI":"10.1038\/sj.bjp.0706435","article-title":"75 years of opioid research: the exciting but vain quest for the Holy Grail","volume":"147","author":"Corbett","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.01.020_bib9","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1124\/jpet.117.246439","article-title":"Application of receptor theory to the design and use of fixed-proportion mu-opioid agonist and antagonist mixtures in rhesus monkeys","volume":"365","author":"Cornelissen","year":"2018","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2019.01.020_bib10","series-title":"Guide for the Care and Use of Laboratory Animals","author":"Council","year":"2011"},{"key":"10.1016\/j.neuropharm.2019.01.020_bib11","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1037\/a0012931","article-title":"Sex differences in analgesic, reinforcing, discriminative, and motoric effects of opioids","volume":"16","author":"Craft","year":"2008","journal-title":"Exp. Clin. Psychopharmacol"},{"key":"10.1016\/j.neuropharm.2019.01.020_bib12","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1124\/jpet.112.201616","article-title":"A G protein-biased ligand at the \u03bc-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine","volume":"344","author":"DeWire","year":"2013","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2019.01.020_bib13","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0022-3565(25)20761-3","article-title":"Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the mu opioid receptor","volume":"278","author":"Emmerson","year":"1996","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2019.01.020_bib14","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/j.1552-4604.1967.tb00029.x","article-title":"Clinical investigation of the analgesic potency and respiratory depressant activity of fentanyl, a new narcotic analgesic","volume":"7","author":"Finch","year":"1967","journal-title":"J. Clin. Pharmacol. J. N. Drugs"},{"key":"10.1016\/j.neuropharm.2019.01.020_bib15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0376-8716(85)90061-4","article-title":"Drug discrimination studies","volume":"14","author":"Holtzman","year":"1985","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2019.01.020_bib16","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0091-3057(96)00395-4","article-title":"Antagonism of morphine-like discriminative effects by \u03b2-funaltrexamine","volume":"57","author":"Holtzman","year":"1997","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2019.01.020_bib17","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/mol.115.099770","article-title":"The effective application of biased signaling to new drug discovery","volume":"88","author":"Kenakin","year":"2015","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.01.020_bib18","article-title":"Pharmacological characters of oliceridine, a mu-opioid receptor G-protein-biased ligand in mice","author":"Liang","year":"2018","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.neuropharm.2019.01.020_bib19","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1124\/jpet.114.216648","article-title":"Impact of efficacy at the mu-opioid receptor on antinociceptive effects of combinations of mu-opioid receptor agonists and cannabinoid receptor agonists","volume":"351","author":"Maguire","year":"2014","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2019.01.020_bib20","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/S0022-3565(24)38224-2","article-title":"Sensitivity to the discriminative stimulus and antinociceptive effects of \u03bc opioids: role of strain of rat, stimulus intensity, and intrinsic efficacy at the \u03bc opioid receptor","volume":"289","author":"Morgan","year":"1999","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2019.01.020_bib21","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00008877-199605000-00007","article-title":"Contribution of individual differences to discriminative stimulus, antinociceptive and rate-decreasing effects of opioids: importance of the drug's relative intrinsic efficacy at the mu receptor","volume":"7","author":"Morgan","year":"1996","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.01.020_bib22","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejphar.2008.11.004","article-title":"Role of delta opioid efficacy as a determinant of mu\/delta opioid interactions in rhesus monkeys","volume":"602","author":"Negus","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.01.020_bib23","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.tips.2018.08.007","article-title":"Abuse potential of biased mu opioid receptor agonists","volume":"39","author":"Negus","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2019.01.020_bib24","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1037\/a0013088","article-title":"Mu\/kappa opioid interactions in rhesus monkeys: implications for analgesia and abuse liability","volume":"16","author":"Negus","year":"2008","journal-title":"Exp. Clin. Psychopharmacol"},{"key":"10.1016\/j.neuropharm.2019.01.020_bib25","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.bmcl.2015.12.024","article-title":"Biased agonism: an emerging paradigm in GPCR drug discovery","volume":"26","author":"Rankovic","year":"2016","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.neuropharm.2019.01.020_bib26","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.cell.2017.10.035","article-title":"Bias factor and therapeutic window correlate to predict safer opioid analgesics","volume":"171","author":"Schmid","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2019.01.020_bib27","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S0022-3565(24)37462-2","article-title":"Signal transduction correlates of mu opioid agonist intrinsic efficacy: receptor-stimulated [35S]GTP\u03b3S binding in mMOR-CHO cells and rat thalamus","volume":"285","author":"Selley","year":"1998","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2019.01.020_bib28","doi-asserted-by":"crossref","first-page":"500","DOI":"10.2105\/AJPH.2017.304265","article-title":"Quantifying the epidemic of prescription opioid overdose deaths","volume":"108","author":"Seth","year":"2018","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.neuropharm.2019.01.020_bib29","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1124\/jpet.116.232421","article-title":"Antinociceptive interactions between the imidazoline I2 receptor agonist 2-BFI and opioids in rats: role of efficacy at the \u03bc-opioid receptor","volume":"357","author":"Siemian","year":"2016","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2019.01.020_bib30","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.2147\/JPR.S137952","article-title":"A randomized, Phase IIb study investigating oliceridine (TRV130), a novel mu-receptor G-protein pathway selective (mu-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty","volume":"10","author":"Singla","year":"2017","journal-title":"J. Pain Res."},{"key":"10.1016\/j.neuropharm.2019.01.020_bib31","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/j.pain.2014.06.011","article-title":"Biased agonism of the mu-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: a randomized, double-blind, placebo-controlled, crossover study in healthy volunteers","volume":"155","author":"Soergel","year":"2014","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2019.01.020_bib32","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1124\/mol.114.096503","article-title":"A novel method for analyzing extremely biased agonism at G protein\u2013coupled receptors","volume":"87","author":"Stahl","year":"2015","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.01.020_bib33","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.pain.2003.08.008","article-title":"Pharmacogenetic analysis of sex differences in opioid antinociception in rats","volume":"106","author":"Terner","year":"2003","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2019.01.020_bib34","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1124\/jpet.103.058602","article-title":"Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at \u03bc- and \u03b4-opioid receptors","volume":"308","author":"Thompson","year":"2004","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2019.01.020_bib35","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1056\/NEJMsr1706626","article-title":"The role of science in addressing the opioid crisis","volume":"377","author":"Volkow","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2019.01.020_bib36","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.neuropharm.2008.01.001","article-title":"Predictive validity of animal pain models? A comparison of the pharmacokinetic\u2013pharmacodynamic relationship for pain drugs in rats and humans","volume":"54","author":"Whiteside","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2019.01.020_bib37","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.neulet.2013.08.033","article-title":"An industry perspective on the role and utility of animal models of pain in drug discovery","volume":"557","author":"Whiteside","year":"2013","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2019.01.020_bib38","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.bmc.2015.02.055","article-title":"Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14beta-dihydroxy-4,5alpha-epoxy-6alpha-(isoquinoline-3'-ca rboxamido)morphinan analogues as opioid receptor ligands","volume":"23","author":"Yuan","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.neuropharm.2019.01.020_bib39","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.drugalcdep.2018.08.002","article-title":"The G-protein biased mu-opioid agonist, TRV130, produces reinforcing and antinociceptive effects that are comparable to oxycodone in rats","volume":"192","author":"Zamarripa","year":"2018","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2019.01.020_bib40","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0022-3565(25)38710-0","article-title":"In vivo determination of mu opioid receptor turnover in rhesus monkeys after irreversible blockade with clocinnamox","volume":"269","author":"Zernig","year":"1994","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2019.01.020_bib41","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejphar.2014.04.041","article-title":"Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14\u03b2-dihydroxy-4,5\u03b1-epoxy-6\u03b1-(isoquinoline-3\u2032-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand","volume":"736","author":"Zhang","year":"2014","journal-title":"Eur. J. Pharmacol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818308268?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818308268?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T06:55:08Z","timestamp":1758437708000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390818308268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":41,"alternative-id":["S0028390818308268"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2019.01.020","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2019.01.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}